These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 38568257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB, Dacic S, Miller C, Cheung S, Churg A.
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [Abstract] [Full Text] [Related]

  • 3. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM.
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [Abstract] [Full Text] [Related]

  • 4. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A, Prabhakaran S, Pulford E, Hocking AJ, Godbolt D, Ziad F, Pandita A, Wessels A, Hussey M, Russell PA, Klebe S.
    Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301
    [Abstract] [Full Text] [Related]

  • 5. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
    Churg A, Naso JR.
    Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L, Le Stang N, Gallob F, Pissaloux D, Sequeiros R, Paindavoine S, Pairon JC, Karanian M, Dacic S, Girard N, Churg A, Tirode F, Galateau-Salle F.
    Arch Pathol Lab Med; 2023 Mar 01; 147(3):313-322. PubMed ID: 35738002
    [Abstract] [Full Text] [Related]

  • 12. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
    Terra S, Roden AC, Yi ES, Aubry MC, Boland JM.
    Am J Clin Pathol; 2022 Jan 06; 157(1):33-39. PubMed ID: 34463336
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K.
    Lung Cancer; 2018 Nov 06; 125():198-204. PubMed ID: 30429020
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, Galateau-Salle F, Hiroshima K, Krausz T, Le Stang N, McGregor S, Nabeshima K, Husain AN.
    Mod Pathol; 2020 Feb 06; 33(2):245-254. PubMed ID: 31231127
    [Abstract] [Full Text] [Related]

  • 18. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2019 Apr 06; 130():187-193. PubMed ID: 30885343
    [Abstract] [Full Text] [Related]

  • 19. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A, Sheffield BS, Galateau-Salle F.
    Arch Pathol Lab Med; 2016 Apr 06; 140(4):318-21. PubMed ID: 26288396
    [Abstract] [Full Text] [Related]

  • 20. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR, Tsuji S, Churg A.
    Am J Surg Pathol; 2020 Aug 06; 44(8):1143-1148. PubMed ID: 32205484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.